Ardelyx Inc. Highlights Strategic Progress and Challenges at the H.C. Wainwright Annual Conference
HYDROGEN
At the H.C. Wainwright 27th Annual Global Investment Conference, Ardelyx Inc. showcased its strategic advancements with IBSRELA and XPHOZAH, reporting an 84% growth in IBSRELA sales. However, Medicare coverage changes pose challenges for patient access.
The company aims for $1 billion in peak sales for IBSRELA and $750 million for XPHOZAH, with ongoing expansions of its sales force and patient access programs. Legal proceedings regarding Medicare coverage for XPHOZAH are underway, with a ruling expected by year-end.
Sep 18, 2025, 7:44 AM
